Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How the Iran war may affect your money and bills - 2To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
- 3The Best Games Crossroads in History
- 4Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- 5From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Russia earning billions from Hormuz blockade, German trade body says
- Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- What happened in 'Wicked' part 1 and will there be a 3rd movie? Recap and what Ariana Grande, Jon M. Chu have said about a sequel.
- Vote in favor of your Favored Travel Movement
- New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu
- Gartex Texprocess India to showcase innovations across textile ecosystem
- Select Your Go-To Bluetooth Earphones
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
